Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response

J Exp Med. 2022 Sep 5;219(9):e20212126. doi: 10.1084/jem.20212126. Epub 2022 Jul 14.

Abstract

Anti-interferon (IFN)-γ autoantibodies (AIGAs) are a pathogenic factor in late-onset immunodeficiency with disseminated mycobacterial and other opportunistic infections. AIGAs block IFN-γ function, but their effects on IFN-γ signaling are unknown. Using a single-cell capture method, we isolated 19 IFN-γ-reactive monoclonal antibodies (mAbs) from patients with AIGAs. All displayed high-affinity (KD < 10-9 M) binding to IFN-γ, but only eight neutralized IFN-γ-STAT1 signaling and HLA-DR expression. Signal blockade and binding affinity were correlated and attributed to somatic hypermutations. Cross-competition assays identified three nonoverlapping binding sites (I-III) for AIGAs on IFN-γ. We found that site I mAb neutralized IFN-γ by blocking its binding to IFN-γR1. Site II and III mAbs bound the receptor-bound IFN-γ on the cell surface, abolishing IFN-γR1-IFN-γR2 heterodimerization and preventing downstream signaling. Site III mAbs mediated antibody-dependent cellular cytotoxicity, probably through antibody-IFN-γ complexes on cells. Pathogenic AIGAs underlie mycobacterial infections by the dual blockade of IFN-γ signaling and by eliminating IFN-γ-responsive cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Autoantibodies
  • Electric Impedance
  • Humans
  • Interferon-gamma
  • Mycobacterium Infections* / genetics
  • Mycobacterium Infections* / microbiology
  • Receptors, Interferon* / genetics

Substances

  • Antibodies, Monoclonal
  • Autoantibodies
  • Receptors, Interferon
  • Interferon-gamma